Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-αA (rIFNαA)

Alexander M. Eggermont, Willem Weimar, Bhupendra Tank, Amelie M. Dekkers-Bijma, Richard L. Marquet, Johannes S. Lameris, Dick L. Westbroek, Johannes Jeekel

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

A total of 20 patients with advanced colorectal cancer received recombinant leukocyte interferon-αA (rIFNαA) either chronically (group I: twice a week up to 20×106 IU/m2 i.m.) or cyclically (group II: 1-4 periods of 8 consecutive days up to 20×106 IU/m2 i.m. daily at 20-days intervals) over a period of 12 weeks. There was 1 partial response, 1 mixed response and 1 patient with stable disease, whilst 17 patients had progressive disease. Median survival was 15.5 months. Survival was significantly shorter when the extent of hepatic disease was >25% (P=0.05), extrahepatic disease was extensive (P<0.005), alkaline phosphatase level was >2× normal (P<0.02), or performance status was <100% (P<0.001). Toxicity consisting mainly of fever, fatigue, anorexia and weight loss was serious in group I and minimal in group II. Administration of rIFNαA led to a "short lived" augmentation of natural killer (NK) cell activity. In the cyclically treated group this was a recurrent phenomenon whereas a marked lasting depression of NK cell activity was seen in chronically treated patients. Interferon-γ production capacity was significantly stimulated during rIFNαA therapy. The differences in toxicity and immunostimulatory effects between the two schedules may be of importance in the design of further studies.

Original languageEnglish
Pages (from-to)81-84
Number of pages4
JournalCancer Immunology, Immunotherapy
Volume21
Issue number1
DOIs
Publication statusPublished - Jan 1986
Externally publishedYes

Fingerprint

Dive into the research topics of 'Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-αA (rIFNαA)'. Together they form a unique fingerprint.

Cite this